

Systemic Viral Delivery of Potent RNA Therapeutics to Hard-to-Treat Cancers




The Need

- ❑ Unmet clinical need: late-stage cancers
- ❑ IO unresponsive ~80B\$ solid tumors market
- ❑ Efficacy limited by systemic toxicity
- ❑ Cytokines work → but can't be safely delivered
- ❑ Viral vectors lack tumor specificity
- ❑ Most viral dose is sequestered by normal tissue

Our Solution: Tumor-Targeted Viral Platform

- ❑ Native viral vector + external engager
- ❑ No coat engineering → full potency retained
- ❑ IV-ready vector
- ❑ Tumor-marker gated entry
- ❑ Programmable payloads: cytokines, immune modulators, checkpoint inhibitors
- ❑ Modular-rapid retargeting across indications

Technology



Pipeline: Expansion-ready

Candidate	Discovery	Lead Opt	Preclinical	Phase 1	Phase 2	Phase 3
VRBx-001 (CEACAM6 Solid tumors)						
VRBx-002 (PSMA Prostate)						
VRBx-003 Novel Targets						

Lead Target: CEACAM6

- ❑ 80-90% of solid tumors (Pancreatic, Lung, Ovarian, Colorectal)
- ❑ Poor prognosis marker

IP & Development Status

- ❑ 2 Patents from Weizmann institute of science, institutional alignment
- ❑ Next IP: viral cassette payloads
- ❑ Initial POC in-vitro, supportive in-vivo
- ❑ External in-vitro and in-vivo validation

Near term developmental plan:


- ❑ **6-9m:** Candidate optimization and selection, efficacy in human relevant models/organoids, ITF/interact
- ❑ **18-24m:** Non-GLP tox, CMC feasibility, pre-IND, platform expansion

Summary

Selective tumor killing
Safe | Flexible | Shielded

Contact

✉ virobixcompany@gmail.com
🌐 www.virobix.com



CEO CO-FOUNDER



Dr. Diana Gataulin

Co-inventor
Therapeutic dev.
BD& Strategy

CSO CO-FOUNDER



Dr. Eyal Zoler

Virology & cytokine
engineering expert
process dev.

SCIENTIFIC ADVISOR



Prof. Menachem Rubinstein

Core technology
inventor; creator of
Roferon-A™, Rebif™
Enbrel™

Partners and traction:



PEARL COHEN

Nucleate

NEST CATALYST

רשות החדשנות
Israel Innovation
Authority



ADRES